Bivalirudina
Seqüência:D-Phe-Pro-Arg-Pro-Gli-Gli-Gli-Gli-Asn-Gli-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH
Alias:126:PN:WO2004076484PÁGINA:31 proteína reivindicada;Angiomax;BG 8967;Bivalirudina;Hirulog; Hirulog 1
Nº de caixa: 128270-60-0
Fórmula molecular: C98H138N24O33
Peso molecular: 2180.29
Pureza (HPLC): 98.0%min.
Aparência: Pó branco
Impureza Única (HPLC): 1.0%máximo
Composição de Aminoácidos: ±10% do teórico
Conteúdo Peptídeo (N%): >80.0%
Teor de Água (Karl Fischer): <8.0%
Teor de Trifluoroacetato(HPIC): >12.0%
EM (ESI): Consistente
Balanço de massa: 95.0~105,0%
Avaliar : Grau Farmacêutico
Armazenar: Fechadas, abaixo de 2 ~ 8℃ preservação
Uso : Este produto é usado principalmente para a prevenção da terapia intervencionista de formação vascular no tratamento da angina instável, complicações isquêmicas antes e depois. Inibe a trombina circulante e ligada ao coágulo, ao mesmo tempo que inibe a ativação e agregação plaquetária mediada pela trombina.
Bivalirudina (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, ao mesmo tempo que inibe a ativação e agregação plaquetária mediada pela trombina. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).
Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.
Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.
